1x10^6 human PBMCs were surface stained with 0.2 ug Anti-Human CD4 (65143-1-Ig, Clone:RPA-T4) or Mouse IgG1 Isotype Control and Multi-rAb CoraLite ® Plus 647-Goat Anti-Mouse Recombinant Secondary Antibody (H+L) (RGAM005) at dilution 1:1000. Cells were then stained with CL488-conjugated Anti-Human CD3 (CL488-65151). Cells were not fixed. Lymphocytes were gated.

1x10^6 human PBMCs were surface stained with 0.2 ug Anti-Human CD4 (65143-1-Ig, Clone:RPA-T4) or Mouse IgG1 Isotype Control and Multi-rAb CoraLite ® Plus 647-Goat Anti-Mouse Recombinant Secondary Antibody (H+L) (RGAM005) at dilution 1:1000. Cells were not fixed. Lymphocytes were gated.

1X10^6 human PBMCs were surface co-stained with FITC Anti-Human CD3 and 5 ul APC Anti-Human CD4 (APC-65143, Clone:RPA-T4) or Mouse IgG1 Isotype Control. Cells were not fixed. Lymphocytes were gated.

1X10^6 human PBMCs were surface stained with 5 ul APC Anti-Human CD4 (APC-65143, Clone:RPA-T4) or Mouse IgG1 Isotype Control. Cells were not fixed. Lymphocytes were gated.

1X10^6 human PBMCs were surface co-stained with CL750 Anti-Human CD3 and 5 ul Atlantic Blue™ Anti-Human CD4 (AB-65143, Clone:RPA-T4), or Mouse IgG1 Isotype Control. Cells were not fixed. Lymphocytes were gated.

1X10^6 human PBMCs were surface stained with 5 ul Atlantic Blue™ Anti-Human CD4 (AB-65143, Clone:RPA-T4), or Mouse IgG1 Isotype Control. Cells were not fixed. Lymphocytes were gated.

1X10^6 human PBMCs were surface co-stained with CoraLite® Plus 750 Anti-Human CD3 and 5 ul Cardinal Red™ Anti-Human CD4 (CR-65143, Clone:RPA-T4) or Mouse IgG1 Isotype Control. Cells were not fixed. Lymphocytes were gated.

1X10^6 human PBMCs were surface stained with 5 ul Cardinal Red™ Anti-Human CD4 (CR-65143, Clone:RPA-T4) (red) or Mouse IgG1 Isotype Control. Cells were not fixed. Lymphocytes were gated.

1X10^6 human PBMCs were surface co-stained with CoraLite® Plus 750 Anti-Human CD3 and 5 ul CoraLite® Plus 405 Anti-Human CD4 (CL405-65143, Clone:RPA-T4) or Mouse IgG1 Isotype Control. Cells were not fixed. Lymphocytes were gated.

1X10^6 human PBMCs were surface stained with 5 ul CoraLite® Plus 405 Anti-Human CD4 (CL405-65143, Clone:RPA-T4) (red) or Mouse IgG1 Isotype Control. Cells were not fixed. Lymphocytes were gated.

1X10^6 human peripheral blood lymphocytes were surface stained with APC Anti-Human CD3 (APC-65151, Clone: UCHT1) and 5.00 ul CoraLite® Plus 488-conjugated Anti-Human CD4 (CL488-65143, Clone: RPA-T4). Cells were not fixed.

1X10^6 human peripheral blood lymphocytes were surface stained with APC Anti-Human CD3 (APC-65151, Clone: UCHT1) and CoraLite® Plus 488-conjugated Mouse IgG1 isotype control antibody. Cells were not fixed.

1X10^6 human PBMCs were surface co-stained with CL750 Anti-Human CD3 and 5 ul CoraLite® Plus 555 Anti-Human CD4 (CL555-65143, Clone:RPA-T4) or Mouse IgG1 Isotype Control. Cells were not fixed. Lymphocytes were gated.

1X10^6 human PBMCs were surface stained with 5 ul CoraLite® Plus 555 Anti-Human CD4 (CL555-65143, Clone:RPA-T4), or Mouse IgG1 Isotype Control. Cells were not fixed. Lymphocytes were gated.

1x10^6 human PBMCs were surface stained with 5 ul CoraLite® Plus 594 Anti-Human CD4 (CL594-65143, Clone:RPA-T4) or CoraLite®594 Mouse IgG1 Isotype Control, and CL488-conjugated Anti-Human CD3. Cells were not fixed. Lymphocytes were gated.

1x10^6 human PBMCs were surface stained with 5 ul CoraLite® Plus 594 Anti-Human CD4 (CL594-65143, Clone:RPA-T4) or CoraLite®594 Mouse IgG1 Isotype Control. Cells were not fixed. Lymphocytes were gated.